Regulatory actions for July 27, 2026
AI Briefing
- • Alfasigma's ibrutinib tablet received US FDA approval for chronic lymphocytic leukemia.
- • Zevra's tafamidis tablet was approved for hereditary transthyretin-mediated amyloidosis in EU.
- • Gilead's filgotinib tablet received EU approval for rheumatoid arthritis treatment.
Source Summary
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Alfasigma, Astrazeneca, Daiichi, Gilead, Mannkind, Menarini, Minoryx, Neuraxpharm, Newamsterdam, Roche, Zevra.
Advertisement